Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating the development of advanced therapeutic strategies with improved efficacy and reduced toxicity. Conventional cancer treatments are often limited by poor drug solubility, non-specific distribution, systemic side effects, and the development of drug resistance. Targeted drug delivery systems, particularly nanotechnology-based approaches, have emerged as promising solutions to overcome these challenges. Solid Lipid Nanoparticles (SLNs) are biocompatible and biodegradable carriers capable of enhancing drug stability, bioavailability, controlled release, and targeted delivery. Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor, is widely used in the treatment of chronic myeloid leukemia; however, its clinical application is constrained by limited bioavailability and adverse effects. Rutin, a natural bioflavonoid, exhibits potent antioxidant, anti-inflammatory, anti-angiogenic, and pro-apoptotic properties, making it a valuable adjunct in cancer therapy. The co-encapsulation of Nilotinib and Rutin into SLNs offers a synergistic therapeutic approach by enhancing solubility, improving cellular uptake, reducing systemic toxicity, and overcoming multidrug resistance. This project focuses on the formulation and application of Nilotinib and Rutin-loaded SLNs as an innovative strategy for enhanced cancer treatment. The SLN-based delivery system holds significant potential for improving therapeutic outcomes and advancing personalized cancer therapy.

Background: Rasmussen encephalitis (RE) is a chronic, progressive encephalitis affecting one hemisphere of the brain. Intractable focal seizures, progressive neurological & cognitive decline and hemispheric atrophy are common clinical and radiological presentations of the disease. Objective: To see the clinical spectrum & short-term treatment outcome of Rasmussen Encephalitis. Method: It was a prospective interventional study, conducted at Department of Pediatric Neurology, Bangabandhu Sheikh Mujib Medical University, Dhaka from July 2022 to July 2023. Total 15 patients with Rasmussen encephalitis were evaluated after IV Methylprednisolone therapy at the doses of 20-30 mg/kg/day. Results: Among 15 patients, 8 (53.3%) were aged 5–10 years and 7 (46.7%) were <5 years; males predominated (11, 73.3%). All presented with seizures, hemiparesis, neuroregression, and cognitive impairment. Dysarthria was observed in 10 (66.7%) and facial nerve palsy in 4 (26.7%). Focal seizures were most common (7, 46.7%), followed by generalized tonic–clonic seizures (3, 20%). EEG showed unihemispheric slowing in 12 (80%) and generalized slowing in 3 (20%). Neuroimaging revealed unihemispheric insular–perisylvian atrophy with basal ganglia involvement in all cases. Following IV methylprednisolone, seizure frequency improved in 13 (86.7%) and EEG improved in 8 (53.3%). Conclusion: All patients with Rasmussen encephalitis presented with seizure, hemiparesis, neuroregression & cognitive impairment. IV Pulse methylprednisolone therapy were effective where seizure frequency reduced more than three-fourth cases & electroencephalographical improvement occured more than half of the cases of all Rasmussen encephalitis.

Type 2 Diabetes Mellitus (T2DM) presents a significant public health burden in Kerala, India, where oxidative stress plays a pivotal role in pathophysiology. This prospective interventional observational study aimed to evaluate the effect of fresh Amla (Phyllanthus Emblica) juice supplementation on Glycated Haemoglobin (HbA1c) levels over a six-month period. The study was conducted at a Government Health Center in Kerala involving 156 patients with diagnosed T2DM (>5 years), baseline HbA1c between 7–9%, and strictly defined criteria excluding smokers and alcohol consumers to isolate the intervention's effect. Participants received daily supplementation of fresh Amla juice (equivalent to four fruits) for six months alongside stable standard pharmacological management. Anthropometric and biochemical parameters were assessed at baseline and six months. The study cohort demonstrated high compliance with the intervention. The mean baseline HbA1c was 8.12 ± 0.54%, decreasing to 7.47 ± 0.48% post-intervention, representing a statistically significant mean reduction of 8.0% from baseline (p < 0.05). No significant adverse events were reported. Adjunctive supplementation with fresh Amla juice resulted in significant glycemic improvement in non-smokers and non-alcoholics, supporting the integration of dietary antioxidants in diabetic care protocols.